VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$29.04$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. SUPN
  4. Financial Ratios

Supernus Pharmaceuticals, Inc. (SUPN) Financial Ratios

Latest Ratios: P/E Ratio 7.9x · EV/EBITDA 6.0x · ROE N/A. (2008–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

SUPN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$3.5B$6.4B$4.8B$4.1B$5.0B$4.5B$3.7B$3.6B$5.0B$6.0B$3.8B
Enterprise Value$3.7B$6.5B$4.9B$4.1B$4.5B$3.7B$3.1B$2.8B$4.3B$5.6B$3.6B
P/E Ratio →7.8730.302410.67——22.26—25.7818.9897.20114.77
P/S Ratio2.585.134.053.755.505.695.704.565.205.203.87
P/B Ratio————96.7022.1544.9717.1575.61——
P/FCF114.29—961.86——14.10—24.8819.0523.6710.09
P/OCF——133.59——12.74—23.7316.4720.229.22

P/E links to full P/E history page with 30-year chart

SUPN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—5.264.103.724.954.654.813.594.494.863.71
EV / EBITDA6.0322.8781.09——15.67—13.6712.9312.8010.22
EV / EBIT13.9622.9588.46——17.04—13.9414.6028.9326.36
EV / FCF——973.06——11.54—19.5616.4422.169.67

SUPN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin80.1%80.1%80.6%84.1%83.2%83.9%85.0%82.2%86.0%89.3%88.6%
Operating Margin21.4%21.4%2.7%-14.3%-9.0%26.9%-24.1%22.7%33.0%36.9%34.9%
Net Profit Margin16.9%16.9%0.2%-11.8%-4.9%25.9%-22.9%17.1%27.4%5.3%3.3%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE————-34.6%143.9%-101.7%97.5%398.0%——
ROA16.6%16.6%0.1%-7.3%-2.4%12.2%-9.3%8.4%17.6%4.6%4.6%
ROIC342.7%342.7%—————————
ROCE79.1%79.1%7.5%-25.4%-9.1%21.7%-16.9%21.7%48.1%110.1%216.9%

SUPN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity————5.401.413.481.403.65——
Debt / EBITDA1.231.236.25——1.22—1.420.721.101.52
Net Debt / Equity————-9.77-4.02-6.99-3.67-10.35——
Net Debt / EBITDA0.550.550.93——-3.47—-3.72-2.05-0.87-0.45
Debt / FCF——11.20——-2.56—-5.33-2.61-1.51-0.42
Interest Coverage6.316.311.34-3.26-2.148.31-6.219.189.523.942.68

SUPN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.710.710.890.981.241.801.981.831.621.430.96
Quick Ratio0.550.550.700.881.121.681.831.731.531.370.92
Cash Ratio0.210.210.340.320.881.371.431.431.131.010.67
Asset Turnover—1.030.900.620.510.430.420.480.620.800.80
Inventory Turnover1.611.611.301.291.321.341.041.921.732.362.70
Days Sales Outstanding—75.1278.0484.8289.1293.21123.5594.85105.7181.7077.23

SUPN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield——————————1.8%
Payout Ratio——————————215.3%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield12.7%3.3%0.0%——4.5%—3.9%5.3%1.0%0.9%
FCF Yield0.9%—0.1%——7.1%—4.0%5.2%4.2%9.9%
Buyback Yield0.3%0.2%3.6%0.8%1.8%2.2%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.3%0.2%3.6%0.8%1.8%2.2%0.0%0.0%0.0%0.0%1.8%
Shares Outstanding—$128M$133M$142M$139M$154M$147M$151M$150M$150M$149M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Negative equity after acquisition

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Multiples Diverge Sharply Across Horizons

Based on reported figures, SUPN trades at a trailing P/E of -38.47 but a forward P/E of 9.46, while EV/EBITDA of 26.16 compares with a forward multiple of 2.45, suggesting the market is pricing a sharp earnings recovery that trailing results do not yet show.

The gap between trailing and forward multiples implies analysts expect earnings to normalize materially from the volatile ten-quarter history, where operating margin ranged from -31.4% to 23.2%. Because the forward EV/EBITDA is far below the trailing figure, the valuation depends heavily on whether recent profitability in 2026Q3 proves durable rather than a single strong period. Investors should monitor whether the forward estimates are supported by consistent operating results before relying on the apparent discount.

High Gross Margins Mask Operating Volatility

As reported in the quarterly income statements, SUPN's gross margin held between 84.6% and 90.1% across all ten quarters, yet operating margin swung from 23.2% in 2024Q3 to -31.4% in 2025Q3, indicating that fixed operating spend amplifies revenue variability.

The stability of gross margin points to a high-value product mix with limited cost-driven variance, so the earnings swings appear to originate below the gross profit line. Compared with the sector, the depth of operating losses in several quarters suggests a cost structure that is heavily exposed to revenue timing. Operating margin is therefore a more informative gauge of earning power here than net margin, which is further distorted by non-operating items.

Returns Oscillate Rather Than Compound

Based on SUPN's reported figures, ROIC moved from 3.1% in 2024Q3 to -4.8% in 2025Q3 and back to 26.4% in 2026Q3, a pattern that reflects erratic earnings rather than sustained capital compounding.

The alternation between positive and negative ROIC suggests returns are driven by lumpy quarterly profit rather than a stable improvement in capital efficiency. The 2026Q3 ROE of 28.2% is inflated by the shrinking equity base following negative book equity, so it may overstate true returns. Peers such as HRMY, with ROIC of 42.0%, show that sustained high returns are achievable in this sector, which makes SUPN's inconsistent record a relative weakness.

Debt Build Pressures Negative Equity Position

According to the supplied balance sheet, SUPN's total debt rose from $40.2M to $501.0M in a single quarter, pushing book equity to -$60.0M and lifting leverage to a level where debt-to-equity is no longer meaningful.

The abrupt jump in debt coincides with the large acquisition outflow, which appears to be the principal driver of the leverage shift. Interest coverage is volatile and unreliable across the period, so debt service comfort cannot be assessed with confidence from these quarters alone. Investors should monitor refinancing terms and the timing of repayment, since the negative equity position limits the reliance that can be placed on book-value-based leverage metrics.

Current Ratio Falls as Obligations Rise

Based on reported figures, SUPN's current ratio declined from 2.08 in 2026Q2 to 0.61 in 2026Q3, while cash of $305.0M provides a partial buffer against the increase in current obligations.

The compression below 1.0 indicates that current liabilities now exceed current assets, a shift that warrants further investigation given the acquisition-related debt build. The $305.0M cash position offers meaningful but not complete coverage, and the quick ratio of 0.50 suggests limited liquid cushion beyond cash. Under severe stress, dependence on continued cash generation would be high, given that quarterly free cash flow has alternated between negative and strongly positive.

Forward Multiple Likely Overstates Recovery

The most commonly misapplied metric here is the forward P/E of 9.46, which may flatter SUPN because it relies on normalized earnings from a business whose quarterly results have alternated between profit and sizable losses.

Forward P/E is typically applied to businesses with predictable earnings, but SUPN's ten-quarter record shows operating margin swinging across more than fifty percentage points, so the forward figure rests on an assumption of stability the history does not support. A more reliable alternative is to normalize earnings across a full cycle or to value the company on cash generation averaged over several periods, rather than on a single forward estimate.

Download Financial Ratios Data

Includes 30+ ratios · 18 years · Updated daily

Consensus & Technical Research Suite
Open SUPN Terminal

SUPN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SUPN — Frequently Asked Questions

Quick answers to the most common questions about buying SUPN stock.

What is Supernus Pharmaceuticals, Inc.'s P/E ratio?

Supernus Pharmaceuticals, Inc.'s current P/E ratio is 7.9x. The historical average is 47.9x.

What is Supernus Pharmaceuticals, Inc.'s EV/EBITDA?

Supernus Pharmaceuticals, Inc.'s current EV/EBITDA is 6.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.2x.

Is SUPN stock overvalued?

Based on historical data, Supernus Pharmaceuticals, Inc. is trading at a P/E of 7.9x. Compare with industry peers and growth rates for a complete picture.

What are Supernus Pharmaceuticals, Inc.'s profit margins?

Supernus Pharmaceuticals, Inc. has 80.1% gross margin and 21.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Supernus Pharmaceuticals, Inc. have?

Supernus Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.